Revised SPC: Renvela (sevelamer carbonate) 800 mg film coated tablets -

Revised SPC: Renvela (sevelamer carbonate) 800 mg film coated tablets
Information type: Drug prescribing
Source: electronic Medicines compendium
Specialities: Paediatric and neonatal medicine | Renal and urologic disorders
Summary
Renvela is now licensed for the control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area (BSA) of >0.75m2) with chronic kidney disease. The entire SPC has been updated to reflect information pertaining to this new indication.
UKMi comment

The SPC notes that for paediatric patients, the oral suspension should be administered, as tablet formulations are not appropriate for this population.
Related links: